Today: 29 April 2026
Browse Category

NASDAQ:ABVX 20 November 2025 - 7 January 2026

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

Abivax shares fell about 5% in U.S. and Paris trading after reporting a nine-month net loss of €254.1 million, up from €136.9 million a year earlier. Cash and cash equivalents stood at €589.7 million as of September 30, expected to fund operations into Q4 2027. Investors weighed widening losses against a strong cash position and ongoing takeover speculation.
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax shares surged 8% to $121.94 Thursday afternoon on heavy volume after fresh takeover rumors involving AstraZeneca. The French biotech’s stock is up about 1,450% year-to-date, fueled by strong Phase 3 ulcerative colitis data and M&A speculation. No deal has been confirmed by either company. Intraday volume reached 3.75 million ADSs, far above recent averages.
20 November 2025
··

Stock Market Today

  • Noteworthy Wednesday Options Activity in RVLV, SOFI, and BE
    April 29, 2026, 3:56 PM EDT. Options trading surged Wednesday for Revolve Group Inc (RVLV), SoFi Technologies Inc (SOFI), and Bloom Energy Corp (BE), key components of the Russell 3000 index. RVLV saw 13,841 contracts traded, driven by strong interest in the $30 strike call expiring May 2026, representing 171% of its average daily volume. SOFI options reached 883,275 contracts, with the $32 strike call for June 2026 leading, marking 163% of its typical daily share volume. BE registered 165,808 contracts, spurred by the $300 strike call expiring May 2026, tallying 163% of its average daily trades. These volumes highlight heightened investor focus on select long-dated call options. Today's data signals notable activity in these names among Russell 3000 components.

Latest article

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

29 April 2026
Vita Coco shares jumped 27% Wednesday after first-quarter net sales rose 37% to $180 million, beating analyst expectations. The company raised its 2026 revenue outlook to $720–$735 million and lifted adjusted EBITDA guidance. Diluted earnings reached $0.50 per share, up from $0.31 a year earlier. Gross margin improved to 39.9% despite higher logistics and tariff costs.
Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

29 April 2026
Marathon Petroleum shares rose 3.2% to $240.05 Wednesday as investors anticipated its May 5 earnings report, following a surge in fuel margins during the first quarter. Phillips 66 and Valero also gained after posting stronger-than-expected results. Marathon’s Robinson refinery in Illinois began planned maintenance in March. U.S. gasoline prices hit $4.18 a gallon, the highest since 2022, according to AAA.
Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

29 April 2026
MaxLinear shares rose about 34% to $69.58 on Wednesday after Loop Capital upgraded the stock and raised its target to $75. The surge followed a first-quarter report showing infrastructure revenue up 136% to become the company’s largest segment. Total revenue climbed 43% to $137.2 million. MaxLinear guided second-quarter revenue to $160–$170 million, citing strong demand for data-center optical products.
Go toTop